Herve Bonnefoi

Summary

Affiliation: Institut Bergoni
Country: France

Publications

  1. ncbi request reprint Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
    Herve Bonnefoi
    Geneva University Hospital, Geneva, Switzerland
    Lancet Oncol 8:1071-8. 2007
  2. doi request reprint Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?
    Herve Bonnefoi
    Bergonié Cancer Institute and University of Bordeaux, Bordeaux Cedex, France
    Eur J Cancer 45:1733-43. 2009
  3. pmc TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
    Herve Bonnefoi
    Institut Bergonie, Universite de Bordeaux, INSERM U916, Bordeaux, France
    Lancet Oncol 12:527-39. 2011
  4. doi request reprint The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours
    Elodie Richard
    INSERM U1218, Bergonie Cancer Institute, University of Bordeaux, 33076, Bordeaux, France
    J Pathol 240:256-261. 2016
  5. doi request reprint Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude
    Marc Debled
    Department of Medical Oncology, Institut Bergonie, Bordeaux, France Electronic address
    Eur J Cancer 51:697-704. 2015
  6. doi request reprint [Oncofertility and breast cancer: Where have we come from, where are we going?]
    Aurélie Chirol
    Institut de lutte contre le cancer, Institut Bergonie, Service de Chirurgie, Bordeaux, France Université de Bordeaux, Bordeaux, France Université de La Réunion, France
    Bull Cancer 102:489-96. 2015
  7. pmc Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells
    Stéphanie Verbeke
    INSERM U916, Bergonie Cancer Institute, University of Bordeaux, 229 Cours de l Argonne, Bordeaux, 33076, France
    Breast Cancer Res 16:504. 2014
  8. doi request reprint Validation of a yeast functional assay for p53 mutations using clonal sequencing
    Richard Iggo
    INSERM U916, Institut Bergonié Comprehensive Cancer Centre, Univ Bordeaux, F 33000, Bordeaux, France
    J Pathol 231:441-8. 2013
  9. doi request reprint Imaging features of sporadic breast cancer in women under 40 years old: 97 cases
    Bénédicte Bullier
    Department of Radiology, Institut Bergonie, Comprehensive Cancer Centre, F 33000, Bordeaux, France
    Eur Radiol 23:3237-45. 2013
  10. doi request reprint Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations
    Frederic Chibon
    Department of Pathology, Institut Bergonie, Bordeaux, France
    Mod Pathol 22:403-9. 2009

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
    Herve Bonnefoi
    Geneva University Hospital, Geneva, Switzerland
    Lancet Oncol 8:1071-8. 2007
    ..The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial...
  2. doi request reprint Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?
    Herve Bonnefoi
    Bergonié Cancer Institute and University of Bordeaux, Bordeaux Cedex, France
    Eur J Cancer 45:1733-43. 2009
    ..Finally, we will discuss why microarray studies have so far failed to identify new targets, and how we might be able to improve on these results through large-scale genotyping of tumours...
  3. pmc TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
    Herve Bonnefoi
    Institut Bergonie, Universite de Bordeaux, INSERM U916, Bordeaux, France
    Lancet Oncol 12:527-39. 2011
    ..TP53 has a crucial role in the DNA damage response. We therefore tested the hypothesis that taxanes confer a greater advantage than do anthracyclines on breast cancers with mutated TP53 than in those with wild-type TP53...
  4. doi request reprint The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours
    Elodie Richard
    INSERM U1218, Bergonie Cancer Institute, University of Bordeaux, 33076, Bordeaux, France
    J Pathol 240:256-261. 2016
    ..This approach opens the door to testing genomically targeted treatment of HR+ tumours in precision medicine programmes. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd...
  5. doi request reprint Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude
    Marc Debled
    Department of Medical Oncology, Institut Bergonie, Bordeaux, France Electronic address
    Eur J Cancer 51:697-704. 2015
    ....
  6. doi request reprint [Oncofertility and breast cancer: Where have we come from, where are we going?]
    Aurélie Chirol
    Institut de lutte contre le cancer, Institut Bergonie, Service de Chirurgie, Bordeaux, France Université de Bordeaux, Bordeaux, France Université de La Réunion, France
    Bull Cancer 102:489-96. 2015
    ....
  7. pmc Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells
    Stéphanie Verbeke
    INSERM U916, Bergonie Cancer Institute, University of Bordeaux, 229 Cours de l Argonne, Bordeaux, 33076, France
    Breast Cancer Res 16:504. 2014
    ..To prevent squamous metaplasia, a common artifact in genetically-engineered breast cancer models, we sought to limit activation of the epidermal growth factor receptor (EGFR) during in vitro cell culture before grafting the cells...
  8. doi request reprint Validation of a yeast functional assay for p53 mutations using clonal sequencing
    Richard Iggo
    INSERM U916, Institut Bergonié Comprehensive Cancer Centre, Univ Bordeaux, F 33000, Bordeaux, France
    J Pathol 231:441-8. 2013
    ....
  9. doi request reprint Imaging features of sporadic breast cancer in women under 40 years old: 97 cases
    Bénédicte Bullier
    Department of Radiology, Institut Bergonie, Comprehensive Cancer Centre, F 33000, Bordeaux, France
    Eur Radiol 23:3237-45. 2013
    ..To evaluate characteristic features of mammography, ultrasound and magnetic resonance imaging (MRI) of sporadic breast cancer in women <40 years and to determine correlations with pathological and biological factors...
  10. doi request reprint Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations
    Frederic Chibon
    Department of Pathology, Institut Bergonie, Bordeaux, France
    Mod Pathol 22:403-9. 2009
    ..Pathological factors, in particular SBR grade 3 and more than 60% Her2+ cells, were significantly correlated with HER2 amplification...